waveLINE-003
waveLINE-003 tests a ROR1-directed ADC added to standard salvage chemotherapy.
Phase 2/3; zilovertamab vedotin (MK-2140) with R-GemOx in transplant-ineligible or post-transplant relapse. Also frontline waveLINE-010 with R-CHP.
Setting
R/R DLBCL after ≥1 line: zilovertamab vedotin + R-GemOx vs R-GemOx
Phase
Phase 3
Sponsor
Merck
Registry
Pages like this
not linked directly; found by shared links- PersonStanley R. Riddell
Shares ROR1, Diffuse large B-cell lymphoma.
- InstitutionUC San Diego Moores Cancer Center
Shares ROR1, Zilovertamab vedotin.